Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
4 articles
Newest firstObjectiveTo systematically review existing research evidence on the disease burden of hereditary pancreatitis (HP) in children, focusing on physical, psychological, social and financial consequences for families. MethodsThe review followed Synthesis Without Meta-analysis (SWiM) and PRSIMA guidelines. A structured search of PubMed, Google Scholar, and EMBASE was conducted. The PCC (Population, Concept, Context) fra…
Open article record in new tab ↗BackgroundAs the deadline for eliminating schistosomiasis approaches, more targeted and effective interventions should be proposed. We aimed to understand the burden among various gender, ages, countries, and continents and to analyze the trends in the burden of schistosomiasis from 1990 to 2041. MethodsThis study utilizes data from the Global Burden of Disease (GBD) 2021 to analyze the schistosomiasis burden tren…
Open article record in new tab ↗ObjectivesWe aimed to assess the risk of autoimmune- and inflammatory post-acute COVID-19 conditions. DesignDescriptive network cohort study. SettingElectronic health records from UK and Dutch primary care, Norwegian linked health registry, hospital records of specialist centres in Spain, France, and Korea, and healthcare claims from Estonia and the US. ParticipantsWe followed individuals between September 2020 an…
BackgroundRespiratory syncytial virus (RSV) causes a substantial burden of acute lower respiratory infection in children under 5 years, particularly in low- and middle-income countries (LMICs). Maternal vaccine (MV) and next-generation monoclonal antibody (mAb) candidates have been shown to reduce RSV disease in infants in phase III clinical trials. The cost-effectiveness of these biologics has been estimated usin…